PHASE II PROSPECTIVE STUDY OF NIRAPARIB IN THE SALVAGE TREATMENT OF PATIENTS WITH METASTATIC/RECURRENT/PERSISTENT UTERINE CERVICAL CARCINOMA: PROOF OF CONCEPT (Translational substudy: Evaluation of molecular markers associated with Niraparib response)
Latest Information Update: 13 Mar 2024
At a glance
- Drugs Niraparib (Primary)
- Indications Carcinoma; Cervical cancer; Uterine cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms NIRACERV
- 08 Mar 2024 Status changed from recruiting to discontinued.
- 10 Dec 2020 New trial record